Claims
- 1. A method of treating asthma comprising administering to a mammal in need of such treatment an effective amount of an amide of formula I:
- wherein:
- E is selected from nitrogen and CZ wherein C is a ring carbon and Z is a substituent defined below, wherein:
- when E is CZ, X and Z are selected from the group consisting of:
- (A) X is ArY wherein Y is a linking group selected from carbonyl, sulfinyl, and sulfonyl and Ar is selected from the group consisting of:
- phenyl substituted with 0-2 substituents selected from halo, hydroxy, cyano, (1-4C)alkyl, and (1-4C)alkoxy, provided that the 4-position of said phenyl may be substituted by fluoro only, and that the said phenyl may not be 3,5-disubstituted;
- six-membered heteroaryl rings containing 1-2 nitrogen atoms as the only heteroatoms;
- five-membered heteroaryl rings containing from 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur; provided that Ar is not 3-chlorophenyl, 3-bromophenyl, 3-iodophenyl, 3-(1-4C)alkylphenyl, or 4-pyridyl when Y is carbonyl, and that Ar is not 5-pyrimidinyl when Y is sulfonyl or carbonyl; and
- Z is selected from hydrogen, cyano, halo, hydroxy, (1-4C)alkyl, and (1-4C)alkoxy;
- (B) X is cyano and Z is selected from the group consisting of phenylthio, phenylsulfinyl, and phenylsulfonyl the phenyl rings of which are substituted with 0-2 substituents selected from halo, hydroxy, cyano, nitro, (1-4C)alkyl, and (1-4C)alkoxy;
- when E is nitrogen, X is independently selected from any of the values for X given above in (A);
- R.sup.2 and R.sup.3
- are independently selected from the group consisting of (1-3C)alkyl substituted by from 0 to 2k+1 groups selected from fluoro and chloro wherein k is the number of carbon atoms in the said (1-3C)alkyl, provided that R.sup.2 and R.sup.3 are not both methyl; or
- together, with the carbon atom to which both R.sup.2 and R.sup.3 are attached, form a 3-5 membered cycloalkyl ring optionally substituted by from 0 to 2m-2 fluoro groups wherein m is the number of carbon atoms in said ring;
- or a pharmaceutically acceptable in vivo hydrolyzable ester of said amide;
- or a pharmaceutically acceptable salt of said amide or said ester.
- 2. A method of treating asthma as claimed in claim 1 wherein said amide of formula I is an amide of formula Id: ##STR3## wherein: X and Z are selected from the group consisting of:
- (A) X is ArY wherein
- Y is a linking group selected from carbonyl, sulfinyl, and sulfonyl and Ar is selected from the group consisting of phenyl, 2-, 3- and 4-fluorophenyl, 2- and 3-chlorophenyl, 2- and 3-cyanophenyl, 2- and 3-hydroxyphenyl, 2- and 3-methoxyphenyl, 2- and 3-methylphenyl, 2-, 3- and 4-pyridyl, 2- and 4-pyrimidinyl, 3- and 4-isothiazolyl, 2- and 4-oxazolyl, 2- and 4-thiazolyl, 2- and 3-furyl, and 2- and 3-thienyl;
- Z is selected from hydrogen, cyano, halo, hydroxy, (1-2C)alkyl, and (1-2C)alkoxy;
- (B) X is CN, Z is phenylsulfonyl;
- R.sup.2 and R.sup.3 are independently selected from the group consisting of (1-3C)alkyl substituted by from 0 to 2k+1 fluoro groups wherein k is the number of carbon atoms in the said (1-3C)alkyl, provided that R.sup.2 and R.sup.3 are not both methyl.
- 3. A method of treating asthma as claimed in claim 2 wherein
- X is ArY and wherein Ar, Y, and Z are selected from the group consisting of:
- (i) Y is sulfonyl, Z is hydrogen, and Ar is selected from the group consisting of:
- phenyl substituted with 0-1 substitutents, selected from phenyl, 2-, 3-, and 4-fluorophenyl, 2- and 3-chlorophenyl, 2- and 3-methoxyphenyl, 2- and 3-cyanophenyl, 2- and 3-hydroxyphenyl, and 2- and 3-methylphenyl;
- six-membered heteroaryl rings selected from 2-, 3- and 4-pyridyl, and 2-pyrimidinyl;
- five-membered heteroaryl rings selected from 2-thienyl and 2-thiazolyl;
- (ii) Y is sulfonyl, Ar is phenyl or 4-pyridyl, and Z is selected from the group consisting of cyano, fluoro, hydroxy, methoxy and methyl; and
- (iii) Y is carbonyl, Z is hydrogen, and Ar is selected from the group consisting of phenyl and 2-pyridyl; and
- R.sup.2 and R.sup.3 are independently selected from the group consisting of
- (i) R.sup.2 is trifluoromethyl and R.sup.3 is selected from methyl, ethyl, and trifluoromethyl; and
- (ii) R.sup.2 is difluoromethyl and R.sup.3 is difluoromethyl.
- 4. A method of treating asthma as claimed in claim 1 wherein said amide is selected from;
- N-[4-(4-Pyridylsulfonyl)phenyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-propanamide;
- S-(-)-N-[4-(4-Pyridylsulfonyl)phenyl]-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide;
- N-[4-(Phenylcarbonyl)phenyl]-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide;
- S-(-)-N-[4-(Phenylcarbonyl)phenyl]-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide;
- N-[4-(4-Pyridylsulfonyl)phenyl]-3,3-difluoro-2-hydroxy-2-difluoromethylpropanamide;
- N-[4-(Phenylcarbonyl)phenyl]-3,3,3-trifluoro-2-hydroxy-2-trifluoromethylmethylpropanamide;
- N-[4-(4-Pyridylsulfonyl)phenyl]-3,3,3-trifluoro-2-hydroxy-2-trifluoromethylpropanamide; or
- N-[3-Hydroxy-4-(4=pyridylsulfonyl)phenyl]-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide.
- 5. A method of treating asthma as claimed in claim 4 wherein said amide is:
- N-[4-(Phenylcarbonyl)phenyl]-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide; or
- S-(-)-N-[4-(Phenylcarbonyl)phenyl]-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide.
- 6. A method of treating asthma as claimed in claim 5 wherein said amide is S-(-)-N-[4-(Phenylcarbonyl)phenyl]-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide.
Priority Claims (2)
Number |
Date |
Country |
Kind |
9116069 |
Jul 1991 |
GBX |
|
9209416 |
Apr 1992 |
GBX |
|
Parent Case Info
This is a divisional of application Ser. No. 08/329,188 filed on Oct. 26, 1994, now U.S. Pat. No. 5,414,999; which is a divisional of U.S. application Ser. No. 08/126,350, filed 24 Sep. 1993, now U.S. Pat. No. 5,382,598; which is a divisional of U.S. application Ser. No. 07/918,982, filed 23 Jul. 1992, now U.S. Pat. No. 5,272,163.
US Referenced Citations (13)
Foreign Referenced Citations (8)
Number |
Date |
Country |
0181568 |
May 1986 |
EPX |
0189142 |
Jul 1986 |
EPX |
0253503 |
Jan 1988 |
EPX |
0274867 |
Jul 1988 |
EPX |
0409414 |
Jan 1991 |
EPX |
0409413 |
Jan 1991 |
EPX |
7008629Q |
Jun 1969 |
NLX |
7008627Q |
Jun 1969 |
NLX |
Non-Patent Literature Citations (2)
Entry |
R. Bayles et al., "The Smiles rearrangement of 2-aryloxy-2-methylpropanamides. Synthesis of N-aryl-2-hydroxy-2-methylpropanamides" Synthesis, (1977), 31-33. |
G. Edwards et al., "Structure-activity relationships of potassium channel openers", Trends in Pharmacological Sciences, (1990), 11, 417-422. |
Divisions (3)
|
Number |
Date |
Country |
Parent |
329188 |
Oct 1994 |
|
Parent |
126350 |
Sep 1993 |
|
Parent |
918982 |
Jul 1992 |
|